| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
As a synthetic intermediate, L-Serine isopropyl ester hydrochloride does not possess a specific biological target. Its role is to provide a protected L-serine derivative with a modified carboxylate group, which can be used for peptide coupling or other chemical transformations. The isopropyl ester group can protect the carboxylic acid during reactions and can be removed to generate the free amino acid. In peptide synthesis, this compound can be coupled with other protected amino acids to form dipeptides or longer chains. Serine is a key amino acid involved in many biological processes, including protein phosphorylation and neurotransmitter synthesis, but the esterified form is not intended to directly interact with biological systems. The compound's "target" is the chemical reaction in organic synthesis.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of L-Serine isopropyl ester hydrochloride is evaluated through its performance in chemical reactions rather than biological assays. In peptide coupling, the compound typically achieves high yields (>95%) when activated with reagents such as HATU or HBTU in the presence of a base like DIEA. The reaction is carried out in solvents like DMF or dichloromethane at room temperature. Quality control includes HPLC purity analysis (≥98%) and characterization by NMR and mass spectrometry. The compound does not exhibit any inherent biological activity, as it is a protected amino acid ester. Its in vitro utility is strictly chemical, serving as a precursor for more complex molecules. |
| ln Vivo |
In vivo activity is not applicable for L-Serine isopropyl ester hydrochloride because the compound is not intended for administration to living organisms. It is exclusively a research chemical and synthetic intermediate. The compound is not formulated for any route of administration, and no animal efficacy or safety studies have been conducted. Any biological activity would only be relevant after the ester is hydrolyzed to free L-serine, but this is not the purpose of the compound. Its utility lies entirely in the chemical synthesis domain.
|
| Enzyme Assay |
The non-cellular experimental workflow for this compound involves standard peptide synthesis procedures. The compound (1.0 equivalent) is dissolved in DMF, and a coupling reagent (e.g., HATU, 1.1 equiv.) and a base (e.g., DIEA, 2 equiv.) are added, followed by the amine component. The reaction is stirred at room temperature for 1-4 hours and monitored by TLC. The product is isolated by extraction and purified by column chromatography. Characterization includes NMR and MS. The isopropyl ester can be selectively removed with TFA or HCl in dioxane.
|
| Cell Assay |
Cell-based assays are not performed with this compound.
|
| Animal Protocol |
Animal experiments are not applicable.
|
| ADME/Pharmacokinetics |
PK properties are not characterized.
|
| Toxicity/Toxicokinetics |
Toxicity: standard laboratory precautions apply; may cause irritation.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
L-Serine isopropyl ester hydrochloride is a useful intermediate for peptide synthesis and organic chemistry. It is not a drug and has no clinical approvals. The compound is for research use only.
|
| Molecular Formula |
C6H14CLNO3
|
|---|---|
| Molecular Weight |
183.63
|
| Exact Mass |
183.066
|
| CAS # |
37592-53-3
|
| PubChem CID |
73947482
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
11
|
| Complexity |
114
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl.N[C@H](C(OC(C)C)=O)CO
|
| InChi Key |
ZQSBPSWEMOKULO-JEDNCBNOSA-N
|
| InChi Code |
InChI=1S/C6H13NO3.ClH/c1-4(2)10-6(9)5(7)3-8;/h4-5,8H,3,7H2,1-2H3;1H/t5-;/m0./s1
|
| Chemical Name |
propan-2-yl (2S)-2-amino-3-hydroxypropanoate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: ≥ 100 mg/mL (544.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4457 mL | 27.2287 mL | 54.4573 mL | |
| 5 mM | 1.0891 mL | 5.4457 mL | 10.8915 mL | |
| 10 mM | 0.5446 mL | 2.7229 mL | 5.4457 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
